Jinyang Gon, HL Biopharma Chairman, "Will Cover Losses from Optimus Fund Investment Damage with Personal Funds"

[Asia Economy Reporter Hyunseok Yoo] Jin Yang-gon, chairman of HL Biopharma, recently disclosed his investment in the Optimus Fund, which has become controversial due to the recent suspension of redemptions. On the 30th, he also announced that he would personally contribute his private shares equivalent to the full amount of any losses to the company through a consignment method, ensuring that the company does not suffer a single penny of loss.

On the 29th, Chairman Jin stated via YouTube, “HL Biopharma’s IR principle is to communicate the facts as they are,” and revealed, “On April 24, HL Biopharma Life Science entrusted 10 billion KRW through NH Investment & Securities, and on June 11, HL Biopharma entrusted 30 billion KRW through Hi Investment & Securities to the Optimus Asset Management fund being sold.” He emphasized that this was because “we trusted the securities firms and the asset manager’s notification that the fund was managed with safe assets such as government bonds,” highlighting that they are victims of an incompletely sold fund.

Chairman Jin stated that since the sale of the Optimus Fund was clearly an illegal and unfair act, he filed a 'claim for the return of unjust enrichment' lawsuit against the sellers at the Seoul Southern District Court the day before, and said, “We will do our utmost to recover the principal.”

He said, “As the final decision-maker, I deeply apologize and will take full responsibility for the entire loss amount,” adding, “I will consign my shares equivalent to the loss amount to the company.” He further added, “Going forward, fund management will be strictly focused on stability, and along with efforts to prevent recurrence, we will continue to disclose major company matters transparently and honestly.”